|
Sep 19
|
MEI Pharma Reports Fiscal Year End 2024 Cash Position
|
|
Jul 22
|
MEI Pharma to Consider Strategic Alternatives
|
|
May 9
|
MEI Pharma Reports Third Quarter Fiscal Year 2024 Results and Operational Highlights
|
|
Apr 11
|
MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344
|
|
Apr 11
|
MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients
|
|
Apr 10
|
MEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology Forum
|
|
Mar 26
|
MEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia
|
|
Mar 9
|
12 Most Undervalued Biotech Stocks To Buy According To Hedge Funds
|
|
Nov 27
|
11 Cheapest Stocks With Biggest Upside
|
|
Nov 17
|
AstraZeneca's (AZN) Capivasertib Gets FDA Nod for Breast Cancer
|